Randomized controlled trial data for successful new drug application for rare diseases in the United States

por Kubota, Yosuke, Narukawa, Mamoru
Publicado 2023

Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan

por Watanabe, Tatsuya, Narukawa, Mamoru
Publicado 2016

Impact of the Economic Status of the Patient’s Country of Residence on the Outcome of Oncology Clinical Trials

por Nishiyama, Saki, Narukawa, Mamoru
Publicado 2022

Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial

por Oda, Yoshihiro, Narukawa, Mamoru
Publicado 2022

A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States

por Hoshino, Yuko, Narukawa, Mamoru
Publicado 2022

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis

por Inoue, Takashi, Narukawa, Mamoru
Publicado 2022

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung c...

por Aboshi, Masayuki, Kaneko, Masayuki, Narukawa, Mamoru
Publicado 2014

Lower-dose prescriptions in the post-marketing situation and the influencing factors thereon

por Ogata, Akiko, Kaneko, Masayuki, Narukawa, Mamoru
Publicado 2019

Approval success rates of drug candidates based on target, action, modality, application, and their combinations

por Yamaguchi, Shingo, Kaneko, Masayuki, Narukawa, Mamoru
Publicado 2021

Factors associated with successful phase III trials for solid tumors: A systematic review

por Otsuka, Yasushi, Kaneko, Masayuki, Narukawa, Mamoru
Publicado 2021

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

por Maeda, Kojiro, Kaneko, Masayuki, Narukawa, Mamoru, Arato, Teruyo
Publicado 2017

Current state of therapeutic development for rare cancers in Japan, and proposals for improvement

por Kawai, Akira, Goto, Toshio, Shibata, Tatsuhiro, Tani, Kenzaburo, Mizutani, Shuki, Nishikawa, Akiyoshi, Shibata, Taro, Matsumoto, Seiichi, Nagata, Kyosuke, Narukawa, Mamoru, Matsui, Shigeyuki, Ando, Masashi, Toguchida, Junya, Monden, Morito, Heike, Toshio, Kimura, Shinya, Ueda, Ryuzo
Publicado 2018